All In Biotech

Free tool

FAERS Monitor: Hemlibra

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761083 or its brand name (Hemlibra, Emicizumab). Reports on generic versions are filed under their own applications.

Reports

12,873

Serious

4,932

38% of reports

Hospitalization

2,071

Death reported

416

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • haemorrhage4,767
  • haemarthrosis890
  • off label use826
  • no adverse event812
  • fall705
  • arthralgia539
  • epistaxis437
  • contusion427
  • head injury382
  • pain352
  • muscle haemorrhage332
  • limb injury257
  • joint injury253
  • injury241
  • mouth haemorrhage240

Reports by year received

View as table
YearReports
20111
20175
2018159
2019318
2020527
2021594
2022973
20232,901
20243,633
20252,066
20261,696

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,041,286 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
haemarthrosisSignal890180.0168.3142,622
muscle haemorrhageSignal332147.3131.844,118
haemorrhageSignal4,76778.076.2347,591
mouth haemorrhageSignal24055.348.612,320
head injurySignal38219.918.16,783
joint injurySignal25319.617.34,392
limb injurySignal25715.613.83,468
epistaxisSignal4379.68.73,349
no adverse eventSignal8127.46.94,468
contusionSignal4277.36.62,305
injurySignal2415.65.0910
fallSignal7053.53.21,252
arthralgiaSignal5392.12.0324
off label use8261.51.4163
pain3520.90.82

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.